These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Predictors of survival and recurrence in the surgical treatment of merkel cell carcinoma of the extremities. Senchenkov A; Barnes SA; Moran SL J Surg Oncol; 2007 Mar; 95(3):229-34. PubMed ID: 17323336 [TBL] [Abstract][Full Text] [Related]
5. A comprehensive review of the treatment of Merkel cell carcinoma. Eng TY; Boersma MG; Fuller CD; Goytia V; Jones WE; Joyner M; Nguyen DD Am J Clin Oncol; 2007 Dec; 30(6):624-36. PubMed ID: 18091058 [TBL] [Abstract][Full Text] [Related]
14. Sentinel lymph node biopsy in patients with Merkel cell carcinoma: an emerging role and the Westmead hospital experience. Howle J; Veness M Australas J Dermatol; 2012 Feb; 53(1):26-31. PubMed ID: 22309327 [TBL] [Abstract][Full Text] [Related]
15. Tumor burden of sentinel lymph node metastasis in Merkel cell carcinoma. Koljonen V; Böhling T; Virolainen S J Cutan Pathol; 2011 Jun; 38(6):508-13. PubMed ID: 21521357 [TBL] [Abstract][Full Text] [Related]
16. Merkel cell carcinoma: assessing the effect of wide local excision, lymph node dissection, and radiotherapy on recurrence and survival in early-stage disease--results from a review of 82 consecutive cases diagnosed between 1992 and 2004. Jabbour J; Cumming R; Scolyer RA; Hruby G; Thompson JF; Lee S Ann Surg Oncol; 2007 Jun; 14(6):1943-52. PubMed ID: 17356954 [TBL] [Abstract][Full Text] [Related]
18. Merkel cell carcinoma: a clinicopathological study of 11 cases. Acebo E; Vidaurrazaga N; Varas C; Burgos-Bretones JJ; Díaz-Pérez JL J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):546-51. PubMed ID: 16164706 [TBL] [Abstract][Full Text] [Related]
19. [Merkel cell carcinoma: Current care]. Girard C; Guillot B Ann Dermatol Venereol; 2010 May; 137(5):402-7; quiz 400, 416. PubMed ID: 20470926 [No Abstract] [Full Text] [Related]
20. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Nowecki ZI; Rutkowski P; Michej W Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]